Angion Biomedica Corp. Has Signed Licensing Option With Memorial Sloan-Kettering Cancer Center For Novel Vaccine Platform

Published: Jan 08, 2009

NEW YORK--(BUSINESS WIRE)--Angion Biomedica Corp. has signed an exclusive world-wide licensing option with Memorial Sloan Kettering Cancer Center in New York City (MSKCC) for a novel vaccine platform developed by Professor Samuel Danishefsky. Professor Danishefsky is the Kettering Chair and Director of the Laboratory for Bioorganic Chemistry at the Sloan-Kettering Institute and the Centennial Professor of Chemistry at Columbia University.

Back to news